October 25, 2010 7:54 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Genzyme Corporation (NASDAQ: GENZ) used its Analyst Day to outline why it thinks the Sanofi bid is too low, but stated that it was not against a sale at an appropriate price, Hapoalim Securities reports.“We would expect Genzyme to hold out for a higher offer and due to the limited opportunities for internal growth at Sanofi, we would also expect Sanofi to eventually make a higher bid,” Hapoalim Securities writes. “While $69 per share is obviously too low for Genzyme, $89 per share is likely too high, and we would expect the two companies to eventually meet in the middle, suggesting a final offer of approximately $79 per share or 9% above current levels.”Genzyme Corporation closed Friday at $72.45.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.